Solid Biosciences Raises $240M in Oversubscribed Private Placement
Event summary
- Solid Biosciences secured $240M in an oversubscribed private placement, closing expected March 9, 2026.
- 14.97M shares sold at $5.61 each, plus pre-funded warrants for 27.81M shares at $5.609 each.
- Investors include Perceptive Advisors, Bain Capital Life Sciences, and RA Capital Management.
- Proceeds to fund pipeline development, business activities, and working capital.
- Leerink Partners and Citigroup acted as joint lead placement agents.
The big picture
Solid Biosciences' $240M raise underscores the continued appetite for gene therapy investments, despite the sector's high-risk profile. The oversubscription suggests strong investor confidence in the company's pipeline, particularly in rare disease treatments. This funding round positions Solid Biosciences to accelerate its clinical programs, but the real test will be in delivering tangible progress in its trials.
What we're watching
- Pipeline Development
- How Solid Biosciences allocates the $240M to advance its neuromuscular and cardiac disease programs.
- Market Dynamics
- Whether the oversubscription reflects renewed investor confidence in gene therapy.
- Execution Risk
- The pace at which Solid Biosciences can translate funding into clinical milestones.
Related topics